Trinity Biotech (TRIB) unveils its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Achieves Profitability Milestone Amid Strategic Turnaround
- Trinity Biotech reports Q1 revenue $7.6M
- Trinity Biotech reaches profitability inflection point, marks major milestone
- Trinity Biotech Gains WHO Approval for Outsourced HIV Test Manufacturing
- Trinity Biotech received WHO approval for offshored, outsources manufacturing